Market revenue in 2022 | USD 466.4 million |
Market revenue in 2030 | USD 2,529.8 million |
Growth rate | 23.5% (CAGR from 2022 to 2030) |
Largest segment | Parenteral |
Fastest growing segment | Inhalational |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Inhalational, Parenteral |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, Novo Nordisk A/S ADR, Medtronic PLC, Adherium Ltd, Tandem Diabetes Care Inc, Propeller Health, Ypsomed Holding AG, AptarGroup Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to connected drug delivery devices market will help companies and investors design strategic landscapes.
Parenteral was the largest segment with a revenue share of 56.17% in 2022. Horizon Databook has segmented the Latin America connected drug delivery devices market based on inhalational, parenteral covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America connected drug delivery devices market, including forecasts for subscribers. This continent databook contains high-level insights into Latin America connected drug delivery devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account